Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Arterial Vascular Engineering AVEI -- Ignore unavailable to you. Want to Upgrade?

To: Lap Tan Hoang who wrote (257)	6/30/1998 9:03:00 AM
From: Jeffrey L. Henken	Respond to of 410

AVE Signs Agreement With Tenet biz.yahoo.com SANTA ROSA, Calif., June 30 /PRNewswire/ -- Arterial Vascular Engineering, Inc. (''AVE'') (Nasdaq: AVEI - news) today announced that it has entered into an agreement with Tenet Healthcare Corporation (NYSE: THC - news) to supply AVE's coronary stent systems. Scott Solano, AVE's President and CEO said, ''Tenet Hospitals represent a significant base of business for AVE. George Quinoy, AVE's Director of Sales, and his National Accounts team have done an outstanding job in constructing a mutually beneficial agreement with this nationally recognized organization. The initial acceptance of AVE technology within Tenet facilities has been outstanding. This agreement enhances our current and future opportunities in bringing AVE stent technology to interventional cardiologists performing procedures in Tenet hospitals.'' Headquartered in Santa Rosa, California, Arterial Vascular Engineering, Inc. is a leading provider of highly specialized stent and balloon angioplasty systems for less invasive treatment of cardiovascular disease. AVE sells its stent and balloon angioplasty systems in more than 40 countries, and its coronary stent systems in the United States. Except for the historical information contained herein, this news release contains forward-looking statements that involve risks and uncertainties, including variations in the level of sales and earnings, the ability to manage growth effectively and to adequately increase personnel, the ability to cost-effectively establish, maintain or manage a suitable sales force, the effects of competition and pricing pressure, the rapid and significant technological change that characterizes the medical device industry and the ability to continue to respond to such technological change, and the ability to successfully introduce and achieve market acceptance for new products and continued demand for products generally, as well as the other risks detailed from time to time in documents filed by AVE with the SEC, including the report on Form 10-K for the year ended June 30,1997. SOURCE: Arterial Vascular Engineering, Inc.

To: Lap Tan Hoang who wrote (257)	6/30/1998 9:20:00 AM
From: Jeffrey L. Henken	Respond to of 410

OFF TOPIC: What have you added to this thread besides one question about TA and a brief discussion of your option strategy. When you start posting some substance I'll pay attention to you. In the meantime good luck with all your investments. There are plenty of investors here and at Yahoo who appreciate someone who takes the time to explain and post as much information as it pertains to AVEI and the industry as I do. You're not one of them. I can live with that for sure. As far as ABMI goes, I agree, lets discuss that on the ABMI thread. If you don't want to discuss it at all that's fine too because this is the AVEI thread. If I was only here touting ABMI, in post after post you would have reason to complain but as it is I have made many more substantial contributions to this thread than you, in my last post alone. I follow this industry, not just the options associated with a single investment in it. I predicted that BSX would buy Schneider, almost to the exact day. You will not keep me from posting anywhere I choose. Regards, Jeff